Clinical Trials on IDH2 Mutation in Belgium

Total 58 results

University Hospital, Ghent
Fox Chase Cancer Center; Ziekenhuis Oost-Limburg

Completed

Use of Recombinant hCG to Prevent Breast Cancer in BRCA1 and BRCA2 Carriers

BRCA1 Mutation | BRCA2 Mutation | hCG

Belgium
Universitaire Ziekenhuizen KU Leuven

Completed

HbA2 Leuven and Its Impact on HbA1c Results (HbA2 Leuven)

Family Study HbA2 Leuven Mutation.

Belgium
AZ-VUB

Unknown

An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation

Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation

Belgium
Vrije Universiteit Brussel

Completed

Strategic Research Program 17 (VUB Funding)

Prosthesis User | Amputation; Traumatic, Limb, Lower

Belgium
AZ-VUB
AstraZeneca; Kom Op Tegen Kanker

Recruiting

Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination Genes (1-2018 BSMO)

Advanced Cancers Harbouring Mutations in HRG

Belgium
Eloxx Pharmaceuticals, Inc.
SGS Life Sciences, a division of SGS Belgium NV

Completed

Phase 1 Study of ELX-02 in Healthy Adult Subjects

Genetic Disease | Nonsense Mutation

Belgium
Eloxx Pharmaceuticals, Inc.
SGS Life Sciences, a division of SGS Belgium NV

Completed

Phase 1 Study of ELX-02 in Healthy Adults

Genetic Disease | Nonsense Mutation

Belgium
Boehringer Ingelheim

Active, not recruiting

A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation

Solid Tumors, KRAS Mutation

Spain, United Kingdom, United States, Belgium
University Medical Center Nijmegen

Recruiting

TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention (TUBA-WISP-II)

Ovarian Cancer | BRCA1 Gene Mutation | BRCA2 Gene Mutation | RAD51C Gene Mutation | RAD51D Gene Mutation | BRIP1 Gene Mutation

Netherlands, United States, Belgium, Norway, Poland, Italy, Australia, Mexico, Brazil, Sweden, Uruguay
Vrije Universiteit Brussel

Unknown

Decoding Motion Planning Using Cortical Potentials

Lower Limb Amputation Above Knee (Injury)

Belgium
Vrije Universiteit Brussel

Completed

Comprehensive Evaluation of the Passive Talaris Demonstrator

Lower Limb Amputation Below Knee (Injury)

Belgium
University Ghent
Fund for Scientific Research, Flanders, Belgium

Completed

Glenohumeral Internal Rotation Deficit (GIRD) (GIRD)

Glenohumeral Internal Rotation Deficit (GIRD)

Belgium
Vrije Universiteit Brussel

Recruiting

Human-Prosthetic Interaction: Brain & Technology After Lower-Limb Loss (HumanIT)

Lower Limb Amputation Below Knee (Injury)

Belgium
Vrije Universiteit Brussel
Université Catholique de Louvain; Fondazione Don Carlo Gnocchi Onlus; University... and other collaborators

Unknown

The CYBERnetic LowEr Imb coGnitive Ortho-prostheis Plus Plus, 2nd Clinical Study (CLs++)

Lower Limb Amputation Above Knee (Injury)

Belgium
Blueprint Medicines Corporation

Completed

(PROSPECTOR) Screening Study Evaluating the Prevalence of the KIT D816V Mutation in Patients With Systemic Mast Cell Activation

Systemic Mast Cell Activation | KIT D816V Mutation

United States, France, United Kingdom, Italy, Germany, Belgium, Spain, Switzerland
International Academy of Osteopathy

Completed

The Effect of the Release of the Intrathoracic Fascia on Thoracic Rotation Mobility

Thoracic | Fascia; Inflammation | Rotation

Belgium
Pfizer

Completed

A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors

Solid Tumors Harboring a BRAF V600 Mutation

United States, France, Italy, Singapore, Australia, Spain, Switzerland, Canada, Belgium
Otto Bock Healthcare Products GmbH

Completed

C-Leg 3 and C-Leg 4 Study in Transfemoral Amputees

Lower Limb Amputation Above Knee (Injury)

Austria, Belgium
Universitaire Ziekenhuizen KU Leuven

Recruiting

LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib (LAT-FLOSI)

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

Belgium
Khondrion BV
Drug Research Unit Ghent, Belgium

Completed

A Dose-escalating Clinical Trial With KH176

Mitochondrial Disease | MELAS | Leigh Syndrome | LHON | Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation

Belgium
Novartis Pharmaceuticals

Active, not recruiting

A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

Advanced Malignancies That Harbor IDHR132 Mutations

Belgium, Germany, Spain, Canada, Australia, United States, Netherlands, Singapore
University Hospital, Antwerp
University Hospital, Ghent

Recruiting

Genome-wide Epistasis for Cardiovascular Severity in Marfan Study (GEMS)

Marfan Syndrome | FBN1 Mutation

Belgium
Pfizer
Medivation, Inc.

Completed

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) (EMBRACA)

Breast Neoplasms | BRCA 1 Gene Mutation | BRCA 2 Gene Mutation

Korea, Republic of, United States, Australia, Spain, Belgium, France, Ireland, Taiwan, Poland, Germany, Israel, Brazil, United Kingdom, Italy, Russian Federation, Ukraine
QED Therapeutics, Inc.
Helsinn Healthcare SA

Terminated

A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma

FGFR2 Gene Mutation | Advanced Cholangiocarcinoma

United States, Belgium, Germany, Italy, Korea, Republic of, Russian Federation, Singapore, Spain, Taiwan, Thailand, United Kingdom
Biogen
Ionis Pharmaceuticals, Inc.

Active, not recruiting

Long-Term Evaluation of BIIB067 (Tofersen)

ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation

United States, Canada, Italy, Belgium, New Zealand, Japan, France, Germany, United Kingdom
AstraZeneca
Daiichi Sankyo Co., Ltd.

Active, not recruiting

A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations (DPT01)

Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast

Italy, Spain, United States, France, Korea, Republic of, Japan, Canada, Denmark, Belgium
Bayer

Recruiting

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

Hong Kong, United States, Taiwan, Spain, Belgium, China, Japan, France, Korea, Republic of, Singapore, Poland, Israel, Italy, Netherlands, Portugal, Brazil
Jasper Gerritsen
Massachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaborators

Recruiting

The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203) (PALSUR)

Glioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult

United States, Belgium, Switzerland, Germany, Netherlands
Jasper Gerritsen
Massachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaborators

Recruiting

The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201) (SUPRAMAX)

Glioblastoma | Brain Neoplasms | Astrocytoma, Grade III | High-grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Brain Neoplasm, Primary | Brain Neoplasm, Malignant | Astrocytoma, Malignant | Brain Neoplasms, Adult

United States, Germany, Belgium, Switzerland, Netherlands
Assistance Publique - Hôpitaux de Paris

Recruiting

Innovative SonoCloud-9 Device for Blood Brain Barrier Opening in First Line Temozolomide Glioblastoma Patients. (SonoFIRST)

Initial Radiological Diagnosis Eligible for Tumor Resection | Initial Radiological Diagnosis Compatible With Newly Diagnosed Glioblastoma (IDH Wild-type) | Eligible for the Standard of Care Including Concurrent Temoradiation and Adjuvant Temozolomide

Belgium, France, Switzerland
Day One Biopharmaceuticals, Inc.

Recruiting

Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors

Melanoma | Colorectal Cancer | Solid Tumor | Non Small Cell Lung Cancer | Bladder Cancer | Thyroid Cancer, Papillary | Pilocytic Astrocytoma | Bladder Urothelial Carcinoma | Non-Small Cell Adenocarcinoma | MEK Mutation | RAS Mutation | Pancreatic Acinar Carcinoma | RAF Mutation | CRAF Gene Amplification | RAF1 Gene Amplification and other conditions

United States, Canada, Korea, Republic of, Spain, Australia, Belgium, France
Jasper Gerritsen
Massachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaborators

Recruiting

The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202) (RESBIOP)

Glioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain

United States, Belgium, Switzerland, Germany, Netherlands
Pierre Fabre Medicament
Clinact

Completed

A Retrospective Non Interventional Study on First Line Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC) (CAPSTAN CRC)

Metastatic Colorectal Cancer | BRAF V600E Mutation Positive

France, United Kingdom, Spain, Belgium, Germany, Italy, Austria
QED Therapeutics, Inc.
Helsinn Healthcare SA

Terminated

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

FGFR2 Gene Mutation | Advanced Cholangiocarcinoma

Korea, Republic of, United States, Belgium, Spain, Taiwan, China, United Kingdom, France, Canada, Germany, Thailand, Italy, Portugal, Australia, Puerto Rico
Amgen

Recruiting

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Advanced Solid Tumors | Kirsten Rat Sarcoma (KRAS) pG12C Mutation

United States, Italy, Taiwan, Spain, United Kingdom, Australia, Austria, Germany, Belgium, Japan, Netherlands, Korea, Republic of, Canada
Puma Biotechnology, Inc.

Terminated

Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations (SUMMIT)

Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

France, United States, Spain, Belgium, United Kingdom, Serbia, Australia, Israel, Canada, Denmark, Ireland, Italy, Korea, Republic of
Jasper Gerritsen
Massachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaborators

Recruiting

The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302) (RECSUR)

Glioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, Malignant

United States, Germany, Netherlands, Switzerland, Belgium
Verastem, Inc.
Amgen

Recruiting

Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients (RAMP203)

Non Small Cell Lung Cancer | KRAS Activating Mutation

United States, Spain, France, United Kingdom, Netherlands, Belgium
Kura Oncology, Inc.

Active, not recruiting

Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy (AIM-HN/SEQ-HN)

HNSCC | HRAS Gene Mutation

United States, Belgium, Spain, United Kingdom, Taiwan, Denmark, Korea, Republic of, Netherlands, Thailand, Germany, Malaysia, Austria, Italy, Greece, Australia, Norway
FORUM Pharmaceuticals Inc

Unknown

Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation

Granulin Mutation

Belgium, United States, France, Italy, Netherlands, United Kingdom
Tesaro, Inc.
European Organisation for Research and Treatment of Cancer - EORTC; Breast... and other collaborators

Terminated

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients (BRAVO)

Ovarian Neoplasms | BRCA1 Gene Mutation | BRCA2 Gene Mutation | Neoplasms, Breast | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Carcinoma of Breast

United States, Spain, Belgium, Israel, United Kingdom, Italy, Poland, Canada, Hungary, Netherlands, France, Portugal, Greece, Iceland
Novartis Pharmaceuticals

Terminated

Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations. (ReTHINK)

Myelofibrosis With High Molecular Risk Mutations

Belgium, Spain, United Kingdom, Hungary, Italy, Japan, Taiwan, Germany, Canada, Singapore, Austria, Australia, France, Israel, Sweden, Switzerland, Hong Kong, Greece, Turkey, Brazil, Russian Federation, Denmark, Portugal, Norway, Poland
Pfizer

Terminated

A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation (REALM-DCM)

Dilated Cardiomyopathy | Lamin A/C Gene Mutation

United States, Spain, Canada, Belgium, Italy, Argentina, Mexico, Netherlands, Norway, United Kingdom
Erasmus Medical Center
Massachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaborators

Recruiting

The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma (RECMAP)

Glioblastoma | Brain Neoplasms | Recurrent Glioblastoma | Recurrent Adult Brain Tumor | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme of Brain | Brain Neoplasms, Adult, Malignant | Astrocytoma, Malignant | Brain Neoplasms, Adult

United States, Germany, Switzerland, Belgium, Netherlands
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy (PYRAMID-1)

Non-squamous NSCLC | HER2 Exon 20 Mutation

Korea, Republic of, United States, Taiwan, Belgium, Spain, China, Australia, Turkey, Italy, France, Germany, Poland, Russian Federation
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

United States, Japan, Taiwan, Spain, Australia, Belgium, Canada, France, Germany, Italy, Korea, Republic of, Poland, United Kingdom
Biogen

Recruiting

A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation (ATLAS)

Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation

United States, Canada, Spain, Australia, Germany, Italy, Japan, Korea, Republic of, United Kingdom, Belgium, Brazil, France, Poland, Sweden
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation

Spain, Italy, Austria, Netherlands, United Kingdom, Germany, Thailand, France, Belgium, China, Argentina, Greece, Turkey, Malaysia, Portugal, Hungary, Brazil, United States, India
Taiho Oncology, Inc.

Recruiting

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) (REZILIENT3)

Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation

United States, Spain, Canada, Italy, Israel, Japan, United Kingdom, Korea, Republic of, Germany, France, Turkey, Belgium, Netherlands, Philippines, Poland, Singapore
Vertex Pharmaceuticals Incorporated

Completed

A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation (TRANSPORT)

Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

United States, France, Spain, Belgium, Canada, Austria, Australia, Germany, United Kingdom, Denmark

Clinical Trials on IDH2 Mutation in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations